Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.71 up 1.18% from its previous closing price of $1.69. In other words, the price has increased by $1.18 from its previous closing price. On the day, 1.68 million shares were traded. LCTX stock price reached its highest trading level at $1.7489 during the session, while it also had its lowest trading level at $1.64.
Ratios:
For a deeper understanding of Lineage Cell Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.08 and its Current Ratio is at 4.08. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 390489248 and an Enterprise Value of 349082240. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.79 while its Price-to-Book (P/B) ratio in mrq is 8.07. Its current Enterprise Value per Revenue stands at 31.985 whereas that against EBITDA is -17.659.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.85, which has changed by 0.9655173 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.80, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 33.01%, while the 200-Day Moving Average is calculated to be 114.20%.
Shares Statistics:
For the past three months, LCTX has traded an average of 1.58M shares per day and 1709860 over the past ten days. A total of 228.36M shares are outstanding, with a floating share count of 215.50M. Insiders hold about 5.63% of the company’s shares, while institutions hold 43.21% stake in the company. Shares short for LCTX as of 1757894400 were 27748083 with a Short Ratio of 17.52, compared to 1755216000 on 26758520. Therefore, it implies a Short% of Shares Outstanding of 27748083 and a Short% of Float of 21.69.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Lineage Cell Therapeutics Inc (LCTX).The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.16 and -$0.21 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.08, with 6.0 analysts recommending between -$0.04 and -$0.13.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $2.3M this quarter.It ranges from a high estimate of $3.3M to a low estimate of $1.35M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $3.78MFor the next quarter, 7 analysts are estimating revenue of $2.08M. There is a high estimate of $3.4M for the next quarter, whereas the lowest estimate is $383k.
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $10.8M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $8.63M. In the same quarter a year ago, actual revenue was $9.5M
